Amplifying KYNA and/or mitigating 3-HK and QUIN, and the use of KMO inhibitor reduced the dystonia and dyskinesia and improved striatal dys-functions through the attenuation of neuroinflammation. The gene discussed is KMO; the disease is drug-induced dyskinesia.